Impaired fibrinolysis and insulin resistance in patients with hypertension

American Journal of Hypertension

Volumn 9, Issue 5, 1996, Pages 484-490

  Jeng, Jing R ^a   Sheu, Wayne H H ^a   Jeng, Chii Y ^a   Huang, Shyuh H ^a   Shieh, Shyh M ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Glucose intolerance; Hypertension; Insulin resistance; Plasminogen activator inhibitor; Tissue plasminogen activator

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; STEADY STATE;

EID: 0030024122     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00442-4     Document Type: Article

References (43)

1. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-278.
2. Gleerup G, Winther K: Decreased fibrinolytic activity and increased platelet function in hypertension: possible influence of calcium antagonist. Am J Hypertens 1991;4:168S-171S.
3. Jansson J-H, Johansson B, Boman K, et al: Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 1991;229:309-316.
4. van Wersch JWJ, Rompelberg-Lahaye J, Lustermans FAT: Plasma concentration of coagulation and fibrinolysis factors and platelet function in hypertension. Eur J Clin Chem Clin Biochem 1991;29:375-379.
5. Glueck CJ, Glueck HI, Hamer T, et al: Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci 1994;307(5):317-324.
6. Ferrannini E, Buzzigoli G, Bonadona R: Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350-357.
7. Shen D-C, Shieh S-M, Fuh M-T, et al: Resistance to inulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988;66:580-583.
8. Swislocki ALM, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance, and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2:419-423.
9. Pollare T, Lithell H, Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39:167-174.
10. Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-141.
11. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-160.
12. Ducimetiere P, Eschwege E, Papoz L, et al: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980;19:2025-210.
13. Fontbonne A, Eschwege E, Cambien F, et al: Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-304.
14. Castelli WP, Doyle JT, Gordon T, et al: HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977; 55:767-772.
15. Juhan-Vague I, Roul C, Alessi MC, et al: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Throm Haemostas 1989;61:370-373.
16. Vague P, Juhan-Vague I, Chabert V, et al: Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 1989;38:913-915.
17. Juhan-Vague I, Alessi MC, Joly P, et al: Plasma plasminogen activator inhibitor in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989;9:362-367.
18. Vague P, Juhan-Vague I, Aillaud MF, et al: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986;35:250-253.
19. Shen S-W, Reaven GM, Farquhar J: Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970;49:2151-2160.
20. Kadish AH, Litle RH, Sternberg JC: A new and rapid method for determination of glucose by measurement of rate of oxygen consumption. Clin Chem 1968; 14:116-131.
21. Allain CA, Poon LS, Chun CSG, et al: Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-475.
22. Wahlefeld AW: Triglyceride. Determination after enzymatic hydrolysis, in Bergmeyer HU (ed): Methods of Enzymatic Analysis. New York, Academic Press, 1974, pp 1831-1835.
23. Bachorik PS, Albers JJ: Precipitation methods for quantification of lipoprotein, in Albers JJ, Segrest JP (eds): Methods in Enzymology, Vol. 129. London, Academic Press, 1986, pp 78-100.
24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:449-502.
25. Kluft C, Jie AFH, Rijken DC, et al: Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fasting acting inhibitor (PAI-1). Thromb Haemost 1989;59:329-332.
26. Rånby M, Sundell IB, Nilsson TK: Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989;62:917-922.
27. Eriksson E, Tengborn L, Risberg B: The effect of various anticoagulant / antiplatelet mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thromb Haemost 1989; 61:511-516.
28. Bergsdorf N, Nilsson T, Wallén P: An enzyme-linked immunosorbent assay for tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 1983;50:740-744.
29. Rånby M, Bergsdorf N, Nilsson T, et al: Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986;32:2160-2165.
30. Declerck PJ, Alessi M-C, Verstreken M, et al: Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71:220-225.
31. Wiman B, Mellbring G, Rånby M: Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127:279-288.
32. Chmielewska J, Rånby M, Wiman B: Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983;31:427-436.
33. Hamsten A, Walldius G, Blombäc KM, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;ii:3-9.
34. Jansson J-H, Nilsson TK, Olofsson B-O: Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157-161.
35. Meade TW, Brozovic M, Chakrabarti R, et al: Haemostatic function and ischemic heart disease: principal resuits of the Northwick Park Heart study. Lancet 1986;i:533-537.
36. Grunlich-Henn J, Müller-Berghaus G: Regulation of endothelial tissue plasminogen activator and plasminogen activator inhibitor type 1 synthesis by diacylglycerol, phorbol ester, and thrombin. Blut 1990;61:38-44.
37. Erickson LA, Ginsberg MH, Loskutoff DJ: Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984;74:1465-1472.
38. Ridker PM, Gaboury CL, Conlin PR, et at: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-1973.
39. Kooistra T, Bosma P, Tons H, et al: Plasminogen activator inhibitor 1: biosythesis and mRNA levels are increased by inulin in cultured human hepatocytes. Thromb Haemostas 1989;62:723-728.
40. Stiko-Rahm A, Wiman B, Harmsten A, et al: Secretion of plasminogen activator inhibitor 1 from culture human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;1067-1073.
41. Latron Y, Alessi MC, Anfosso F, et al: Effect of low density lipoproteins on secretion of plasminogen activator inhibitor 1 (PAI-1) by human endothelial cells and hepatoma cells. Fibrinolysis 1990;4 (suppl 2):82,83.
42. Palermo A, Bertalero P, Pizza N, et al: Decreased fibrinolytic response to adrenergic stimulation in hypertensive patients. J Hypertens 1989;7(suppl 6):S162-S163.
43. Gader AMA, da Costa J, Parker SM, et al: The systemic release of plasminogen activator to intravenous adrenaline in man: dose response studies. Thromb Res 1973;3:51-57.